Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Stratigos AJ, et al. Among authors: bowler t. Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000246 Free article. Clinical Trial.
Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST.
Liu M, Etherington MS, Hanna A, Medina BD, Vitiello GA, Bowler TG, Param NJ, Levin L, Rossi F, DeMatteo RP. Liu M, et al. Among authors: bowler tg. Cancer Immunol Res. 2021 May;9(5):542-553. doi: 10.1158/2326-6066.CIR-20-0692. Epub 2021 Mar 1. Cancer Immunol Res. 2021. PMID: 33648985 Free PMC article.
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, Wong P, Singer S, Ariyan C, Bartlett EK, Crago A, Yoon S, Hwang S, Erinjeri JP, Qin LX, Tap WD, D'Angelo SP. Kelly CM, et al. Among authors: bowler t. JAMA Oncol. 2020 Mar 1;6(3):402-408. doi: 10.1001/jamaoncol.2019.6152. JAMA Oncol. 2020. PMID: 31971541 Free PMC article. Clinical Trial.
Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions.
Bowler TG, Pradhan K, Kong Y, Bartenstein M, Morrone KA, Sridharan A, Kessel RM, Shastri A, Giricz O, Bhagat TD, Gordon-Mitchell S, Rohanizadegan M, Hooda L, Datt I, Przychodzen BP, Parmar S, Maqbool S, Maciejewski JP, Steidl U, Greally JM, Verma A. Bowler TG, et al. Leuk Lymphoma. 2019 Dec;60(13):3132-3137. doi: 10.1080/10428194.2019.1630620. Epub 2019 Jul 10. Leuk Lymphoma. 2019. PMID: 31288594
ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor.
Zeng S, Seifert AM, Zhang JQ, Kim TS, Bowler TG, Cavnar MJ, Medina BD, Vitiello GA, Rossi F, Loo JK, Param NJ, DeMatteo RP. Zeng S, et al. Among authors: bowler tg. Oncotarget. 2017 Dec 11;8(69):114195-114209. doi: 10.18632/oncotarget.23173. eCollection 2017 Dec 26. Oncotarget. 2017. PMID: 29371979 Free PMC article.
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.
Vitiello GA, Medina BD, Zeng S, Bowler TG, Zhang JQ, Loo JK, Param NJ, Liu M, Moral AJ, Zhao JN, Rossi F, Antonescu CR, Balachandran VP, Cross JR, DeMatteo RP. Vitiello GA, et al. Among authors: bowler tg. Clin Cancer Res. 2018 Feb 15;24(4):972-984. doi: 10.1158/1078-0432.CCR-17-2697. Epub 2017 Dec 15. Clin Cancer Res. 2018. PMID: 29246941 Free PMC article.
Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.
Burgoyne AM, De Siena M, Alkhuziem M, Tang CM, Medina B, Fanta PT, Belinsky MG, von Mehren M, Thorson JA, Madlensky L, Bowler T, D'Angelo F, Stupack DG, Harismendy O, DeMatteo RP, Sicklick JK. Burgoyne AM, et al. Among authors: bowler t. JCO Precis Oncol. 2017;2017:PO.17.00014. doi: 10.1200/PO.17.00014. Epub 2017 Aug 15. JCO Precis Oncol. 2017. PMID: 29938249 Free PMC article.
17 results